8:20 am Chair’s Opening Remarks: The Value Proposition of Early Identification & Intervention of Kidney Disease

What’s Next? Opportunities for Additional Drug Development & Addressing Multiple Areas with Treatment

8:30 am Interplay Between Diabetes, Heart failure & CKD: What Can we Learn from Novel Drug Development?

  • Jyothis George Vice President, Clinical, Medical & Regulatory, Novo Nordisk

9:30 am Panel Discussion: Demonstrating Opportunity in Renal to Support a Business Case:

  • Jyothis George Vice President, Clinical, Medical & Regulatory, Novo Nordisk
  • Uptal Patel Executive Director of Clinical Research & Head of Nephrology, Gilead
  • Sibylle Hauske Senior Medical Director & Global Clinical Development Lead - Empagliflozin in CKD, Boehringer Ingelheim
  • Richard Nkulikiyinka VP, Head of Therapeutic Area Cardiology & Nephrology, Bayer Pharmaceuticals

10:00 am Speed Networking

10:45 am Morning Break & Networking

Translational Drug Development Track

Clinical Drug Development Track

Accessing & Interrogating Data to Inform Drug Target Discovery

11.15 Tissue Transcriptomics to Understand Molecular Mechanisms of Progressive CKD & Mechanism-based Patient Stratification

Wenjun Ju, Associate Research Scientist of Internal Medicine, University of Michigan

 

 

Disease Modeling for More Predictive Translation & Mechanistic Discovery

11.45 Applications of Kidney Organoid Disease Models to Optimize Drug Discovery Opportunity

Beno Freedman, Assistant Professor – Nephrology, University of Washington

 

12.15 Bioengineering Technologies to Model Renal Systems

Jonathan Himmelfarb, Director of the Kidney Research Institute & Professor of Medicine, University of Washington

 

Considerations & Tools to Inform Clinical Decisions & Success

11.15 Biomarkers as Key Drug Development Tools

Vishal Vaidya, Translational Omics Group Head, Pfizer

 

11.45 From Diagnostic to Therapeutic Targets

Tzu-Ling (Karen) Tseng, Chief Executive Officer, Bio Preventive Medicine Corp

 

12.15 Renal Function Surrogates for Trial Endpoints & Clinical Decision Support: Are we Reshuffling an Old Deck or Adding New Cards to the Table?

Joseph Stavas Senior Vice President, Clinical
Development, inRegen

12:45 pm Lunch Break

Implementing Precision Medicine in Renal Disease Studying Genetic Drivers & Targetable Mutations in Chronic Kidney Disease

1:45 pm Panel Discussion: Advantages & Disadvantages of Targeting Trials to Specific Orphan Indications Versus Larger Public Health Problems

  • Josh Tarnoff Chief Executive Officer, NephCure Kidney International
  • Uptal Patel Executive Director of Clinical Research & Head of Nephrology, Gilead
  • Dorothee Oberdhan Associate Director, Health Outcomes, Otsuka Pharmaceuticals

2:15 pm Pathway Driven Patient Stratification in Glomerular Disease: A Report From the Trenches

  • Matthias Kretzler Professor of Medicine Nephrology/ Internal Medicine & Bioinformatics, University of Michigan

2:45 pm APOL1 – A Genetic Driver of Kidney Disease: From Concept to Clinical Trials

3:15 pm Afternoon Break & Poster Session

4:00 pm Targeting FSGS as an Entry Point in CKD: Expanding From a Smaller Market

  • Liron Walsh Vice President of Translational & Clinical Nephrology, Goldfinch Bio

4:30 pm Panel Discussion: Executing Precision Medicine in Clinical Trials

  • Matthias Kretzler Professor of Medicine Nephrology/ Internal Medicine & Bioinformatics, University of Michigan
  • Liron Walsh Vice President of Translational & Clinical Nephrology, Goldfinch Bio
  • Jeremy Duffield Global Head of Human Biology, Vertex Pharmaceuticals
  • Andrew King Head of Renal Discovery & Translational Medicine, Chinook Therapeutics

5:00 pm Chair’s Closing Remarks